<DOC>
	<DOCNO>NCT00166322</DOCNO>
	<brief_summary>This study investigation dopaminergic neurotransmission patient schizophrenia , patient risk development schizophrenia , healthy control use iodobenzamide-single photon emission compute tomography ( IBZM-SPECT ) imaging technique amphetamine challenge .</brief_summary>
	<brief_title>Dopaminergic Neurotransmission Schizophrenia , Patients Risk Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>Clinical diagnosis schizophrenia ( currently unmedicated ) Subjects risk development schizophrenia ( prodromal symptom ) Healthy subject Written informed consent Neurological severe somatic disorder Women pregnancy lactation Occupational exposition radiation &gt; 15mSv Medication know interfere IBZM Contraindications use amphetamine challenge</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>IBZM-SPECT</keyword>
	<keyword>Amphetamine Challenge</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>dopaminergic neurotransmission</keyword>
	<keyword>Persons risk development schizophrenia</keyword>
	<keyword>healthy subject</keyword>
</DOC>